Erbitux Solution
Product Images NDC 66733-948

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Erbitux (NDC 66733-948). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Imclone Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Erbitux 100mg Vial (Erbitux 100mg 009 02)

ERBITUX 100 mg/50 mL (2 mg/mL) solution for injection, cetuximab, label for intravenous use. The label includes dosage details, administration and storage instructions, manufacturer ImClone LLC, and distributor Eli Lilly and Company. It features the brand and generic names, NDC 66733-948-23, and safety warnings such as 'DO NOT DILUTE' and 'Rx only.'*

FDA Label Image

Erbitux 200mg Vial (Erbitux 200mg 010 03)

ERBITUX cetuximab injection 200 mg/100 mL (2 mg/mL) solution for intravenous use. The label indicates it is Rx only and includes storage instructions to refrigerate at 2°C to 8°C without freezing or shaking. Manufactured by ImClone LLC, distributed by Eli Lilly and Company. The packaging includes usage directions, contents, and a barcode.*

FDA Label Image

Figure 1 (Erbitux Uspi F1v1)

A survival curve graph comparing the proportion of patients alive over time in months between two groups: CET+CT (cetuximab plus chemotherapy) and CT (chemotherapy alone). The graph includes a table showing the number of patients at risk in each group at various time points up to 24 months.*

FDA Label Image

Figure 2 (Erbitux Uspi F2v1)

A survival curve graph showing proportion of patients alive over time in months for two groups: CET+CT and CT. The chart includes a table below indicating the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure 3 (Erbitux Uspi F3v1)

A Kaplan-Meier survival curve chart showing the proportion of patients alive over time in months. It compares two groups: ERBITUX (cetuximab) plus best supportive care (BSC) versus BSC alone. The x-axis represents time in months, and the y-axis shows the proportion of patients alive. The chart includes the number of patients at risk at various time points for each group.*

FDA Label Image

Erbitux Uspi F4v1

A Kaplan-Meier survival curve chart comparing the probability of survival over 22 months between patients treated with ERBITUX plus encorafenib and a control group. The graph shows higher survival probability for the ERBITUX plus encorafenib group, with the x-axis representing months and the y-axis representing survival probability. Patient counts at risk are listed below the x-axis for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.